Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

Frontiers in Oncology(2021)10.3389/fonc.2021.642466Source: DataRank Database

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia is a research paper published in Frontiers in Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (15)IDs (PubMed, PMC)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Nicole Manning,Christina Sexton ORCID,Eric O’Brien ORCID,Luke Byerly ORCID,Cody Stillwell

Live enrichment

PubMed:33928030 PMC:PMC8076590

NCI NIH HHS

Grant: R50 CA211404

National Institutes of Health

Grant: 5P30AR070549-03

Cincinnati Rheumatic Diseases Resource Center

National Institutes of Health

Grant: 5R01CA215504-04

Instructive role of MLL fusion proteins in lineage determination and leukemogenesis

National Institutes of Health

Grant: 5R01CA204895-04

Leukemia stem cell polarity and differentiation therapy

National Institutes of Health

Grant: 5R50CA211404-04

Therapeutic insights through patient derived leukemia xenografts

goldLicense: cc-by

publisherhttps://www.frontiersin.org/articles/10.3389/fonc.2021.642466/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8076590

repositoryhttps://doaj.org/article/5dda746341a54c8bacc19c67b5f3d649

Europe_PMChttps://europepmc.org/articles/PMC8076590

Europe_PMChttps://europepmc.org/articles/PMC8076590?pdf=render

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

PD-1B-allHumanized MiceBlinatumomabBispecific T-cell EngagerPatient Derived XenograftImmune Checkpoint InhibitionPembrolizumabCancer ResearchNeoplasms. Tumors. Oncology. Including cancer and carcinogensOncologyRC254-282

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good health

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

FAIR Checklist

Authors (9)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)